Gilead Sciences Inc. (GILD): Price and Financial Metrics
GET POWR RATINGS... FREE!
GILD POWR Grades
- GILD scores best on the Value dimension, with a Value rank ahead of 94.74% of US stocks.
- The strongest trend for GILD is in Quality, which has been heading up over the past 26 weeks.
- GILD ranks lowest in Momentum; there it ranks in the 5th percentile.
GILD Stock Summary
- With a market capitalization of $110,323,288,606, GILEAD SCIENCES INC has a greater market value than 98.1% of US stocks.
- GILEAD SCIENCES INC's stock had its IPO on January 22, 1992, making it an older stock than 84.3% of US equities in our set.
- Of note is the ratio of GILEAD SCIENCES INC's sales and general administrative expense to its total operating expenses; only 18.15% of US stocks have a lower such ratio.
- Stocks that are quantitatively similar to GILD, based on their financial statements, market capitalization, and price volatility, are ADI, SNY, RTX, DE, and AMGN.
- GILD's SEC filings can be seen here. And to visit GILEAD SCIENCES INC's official web site, go to www.gilead.com.
GILD Valuation Summary
- GILD's price/earnings ratio is 33.1; this is 43.29% higher than that of the median Healthcare stock.
- GILD's price/earnings ratio has moved down 10.7 over the prior 243 months.
Below are key valuation metrics over time for GILD.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| GILD | 2022-12-05 | 4.1 | 5.2 | 33.1 | 23.7 |
| GILD | 2022-12-02 | 4.1 | 5.3 | 33.5 | 24.0 |
| GILD | 2022-12-01 | 4.1 | 5.2 | 33.1 | 23.7 |
| GILD | 2022-11-30 | 4.1 | 5.2 | 33.0 | 23.7 |
| GILD | 2022-11-29 | 4.0 | 5.1 | 32.3 | 23.2 |
| GILD | 2022-11-28 | 3.9 | 5.1 | 32.1 | 23.1 |
GILD Growth Metrics
- Its 5 year price growth rate is now at 9.89%.
- Its 4 year net cashflow from operations growth rate is now at -45.19%.
- Its 4 year cash and equivalents growth rate is now at 22.14%.
The table below shows GILD's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 27,136 | 9,710 | 3,334 |
| 2022-06-30 | 27,515 | 10,100 | 4,137 |
| 2022-03-31 | 27,472 | 10,614 | 4,515 |
| 2021-12-31 | 27,305 | 11,384 | 6,225 |
| 2021-09-30 | 27,482 | 10,095 | 7,394 |
| 2021-06-30 | 26,638 | 9,092 | 5,162 |
GILD's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- GILD has a Quality Grade of B, ranking ahead of 89.87% of graded US stocks.
- GILD's asset turnover comes in at 0.406 -- ranking 114th of 682 Pharmaceutical Products stocks.
- ENTA, RDUS, and ADMS are the stocks whose asset turnover ratios are most correlated with GILD.
The table below shows GILD's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.406 | 0.805 | 0.259 |
| 2021-06-30 | 0.402 | 0.801 | 0.179 |
| 2021-03-31 | 0.405 | 0.806 | 0.066 |
| 2020-12-31 | 0.403 | 0.815 | 0.058 |
| 2020-09-30 | 0.389 | 0.790 | 0.058 |
| 2020-06-30 | 0.375 | 0.786 | 0.009 |
GILD Price Target
For more insight on analysts targets of GILD, see our GILD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $75.84 | Average Broker Recommendation | 1.7 (Moderate Buy) |
GILD Stock Price Chart Interactive Chart >
GILD Price/Volume Stats
| Current price | $89.47 | 52-week high | $89.61 |
| Prev. close | $87.79 | 52-week low | $57.17 |
| Day low | $87.56 | Volume | 6,392,161 |
| Day high | $89.61 | Avg. volume | 8,623,291 |
| 50-day MA | $76.39 | Dividend yield | 3.33% |
| 200-day MA | $65.60 | Market Cap | 112.22B |
Gilead Sciences Inc. (GILD) Company Bio
Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases. Daniel O’Day has been Gilead Science’s Chief Executive Officer since March of 2019 and the company is headquartered in Foster City, California. With over 10,000 employees worldwide, the company has operations in North America, Asia, the Middle East and Europe. As of 2019, the company had global sales of $22.1 billion. Some of Gilead Science’s major competitors are Novo Nordisk A/S ADR (NVO), Biogen Inc. (BIIB), and Novartis AG ADR (NVS).
Latest GILD News From Around the Web
Below are the latest news stories about GILEAD SCIENCES INC that investors may wish to consider to help them evaluate GILD as an investment opportunity.
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in JapanSANTA MONICA, Calif. & TOKYO, December 07, 2022--Kite Pharma, Inc., a Gilead Company, (hereafter Kite) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) today jointly announced the revision of their 2017 partnership agreement, which gave Daiichi Sankyo exclusive rights to develop, manufacture and commercialize Yescarta (axicabtagene ciloleucel) in Japan. Kite was acquired by Gilead Sciences, Inc. later in 2017 after the Daiichi Sankyo partnership agreement. Daiichi Sankyo and Kite have no |
Wall Street Bulls Look Optimistic About Gilead (GILD): Should You Buy?The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock? |
Should Gilead Sciences, Inc. (NASDAQ:GILD) Focus On Improving This Fundamental Metric?Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is... |
The Zacks Analyst Blog Highlights Exxon Mobil, WesBanco, S&T Bancorp, Gilead Sciences and Conagra BrandsExxon Mobil, WesBanco, S&T Bancorp, Gilead Sciences and Conagra Brands are included in this Analyst Blog. |
New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast CancerFOSTER CITY, Calif., December 06, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from a post-hoc analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and at least two chemotherapies. In the analysis, Trodelvy improved progression-free survival (PFS), overall surviva |
GILD Price Returns
| 1-mo | 8.80% |
| 3-mo | 38.61% |
| 6-mo | 50.83% |
| 1-year | 34.45% |
| 3-year | 51.83% |
| 5-year | 46.32% |
| YTD | 27.78% |
| 2021 | 29.95% |
| 2020 | -6.70% |
| 2019 | 7.88% |
| 2018 | -9.92% |
| 2017 | 2.96% |
GILD Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching GILD
Want to do more research on Gilead Sciences Inc's stock and its price? Try the links below:Gilead Sciences Inc (GILD) Stock Price | Nasdaq
Gilead Sciences Inc (GILD) Stock Quote, History and News - Yahoo Finance
Gilead Sciences Inc (GILD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...